Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Next Previous
X
Search
Trial Profile

Pilot Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 27 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Briquilimab (Primary) ; Alemtuzumab; Cyclophosphamide
  • Indications Chronic granulomatous disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Sep 2024 Planned number of patients changed from 30 to 38.
    • 03 May 2024 According to Jasper Therapeutics media release, data from this trial presented at the 2024 Clinical Immunological Society (CIS) Annual Meeting
    • 04 Jan 2023 Planned initiation date changed from 9 Jan 2023 to 10 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top